Valneva (VALN) said Tuesday the European Commission granted marketing authorization for the Ixchiq vaccine to prevent chikungunya in adolescents aged 12 and older.
The approval was based on data from a six-month Phase 3 study in Brazil, which showed that a single dose induced a high immune response in 99.1% of adolescents.
The company said Ixchiq is now approved for adults and adolescents in the European Union, alongside approvals in the US, UK, and Canada.
Shares of Valneva were up over 1% in recent trading.
Price: 6.79, Change: +0.08, Percent Change: +1.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。